Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

about

Advances in adrenal tumors 2018

P2860

Q57177998-3FD2E9F2-5CD5-4FB0-ACCC-797508F5CB6F

P2860

Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

Item

http://www.wikidata.org/entity/Q38706908

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

@en

type

Item

label

Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

@en

prefLabel

Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

@en

P1476

Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

@en

P2093

Bangqi Wang

http://www.w3.org/2001/XMLSchema#string

Lei Zhang

http://www.w3.org/2001/XMLSchema#string

Minjie Wang

http://www.w3.org/2001/XMLSchema#string

Weilie Hu

http://www.w3.org/2001/XMLSchema#string

Xu Zhao

http://www.w3.org/2001/XMLSchema#string

Yi Zhu

http://www.w3.org/2001/XMLSchema#string

Yigao Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of CTNNB1 signaling in gastric cancer and stem cells

The challenge of developmental therapeutics for adrenocortical carcinoma

Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway

Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies.

Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers.

Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center

Loss of β-catenin in adrenocortical cancer cells causes growth inhibition and reversal of epithelial-to-mesenchymal transition

A functional connectome: regulation of Wnt/TCF-dependent transcription by pairs of pathway activators.

Combined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma.

Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin

P304

22825-22834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.15221

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28423559

http://www.w3.org/2001/XMLSchema#string

P932

5410265

http://www.w3.org/2001/XMLSchema#string

Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

about

P2860

P2860

Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932